Patient baseline characteristics before conditioning therapy and association with high-grade ICANS
| Baseline characteristics . | Total (N = 100) . | Grade 0-2 ICANS (n = 59) . | Grade ≥3 ICANS (n = 41) . | P . |
|---|---|---|---|---|
| Age, median [range], y | 60 [18-85] | 60 [18-85] | 60 [24-85] | .94 |
| Male | 74 (74) | 46 (78) | 28 (68) | .36 |
| ECOG performance status >0 | 69 (69) | 36 (61) | 33 (80) | .05 |
| Diffuse LBCL* | 77 (77) | 47 (80) | 30 (73) | .70 |
| Ann Arbor stage III-IV | 84 (84) | 50 (85) | 34 (83) | 1 |
| IPI score 3-4 | 55 (55) | 28 (47) | 27 (66) | .10 |
| Prior neuro-psychiatric disease | 41 (41) | 26 (44) | 15 (37) | .54 |
| Disease site | ||||
| Head and neck involvement | 40 (40) | 22 (37) | 18 (44) | .54 |
| Bone marrow biopsy involvement | 22 (22) | 17 (29) | 5 (12) | .05 |
| Prior CNS lymphoma | 8 (8) | 3 (5) | 5 (12) | .27 |
| Previous treatment | ||||
| Previous therapies, median [range], n | 4 [2-15] | 4 [2-15] | 4 [2-11] | |
| Refractory disease | 89 (89) | 53 (90) | 36 (88) | .76 |
| Previous autologous SCT | 29 (29) | 16 (27) | 13 (32) | .66 |
| Previous CAR T therapy | 5 (5) | 4 (7) | 1 (2) | .65 |
| Blood counts, median [range] | ||||
| Absolute neutrophil count, ×109/L | 2.8 [0-20] | 2.8 [0-20] | 2.9 [0-18] | .86 |
| Absolute lymphocyte count, ×109/L | 0.6 [0-2] | 0.6 [0-2] | 0.5 [0-1.4] | .54 |
| Absolute monocyte count, ×109/L | 0.5 [0.02-2] | 0.6 [0.06-2] | 0.4 [0.02-1.4] | .22 |
| Hemoglobin, g/dL | 10 [5-16] | 10 [5-16] | 10 [6-14] | .59 |
| Platelet count, ×109/L | 141 [9-391] | 140 [9-391] | 141 [9-389] | .88 |
| Inflammatory markers, median [range] | ||||
| C-reactive protein, mg/L | 33 [0.3-284] | 23 [0.7-275] | 37 [0.3-284] | .44 |
| Ferritin, mg/L | 812 [13-38 964] | 690 [13-4395] | 1 088 [187-38 964] | .23 |
| Albumin, g/dL | 3.8 [2.4-4.9] | 3.9 [2.5-4.9] | 3.7 [2.4-4.6] | .04 |
| Disease burden markers, median [range] | ||||
| LDH fold increase above ULN | 1.4 [0-17.4] | 1.3 [0-8.4] | 1.6 [0.3-17.4] | .09 |
| LDH > ULN | 74 (74) | 41 (69) | 33 (80) | .25 |
| Renal function and electrolytes, median [range] | ||||
| Creatinine clearance, mL/min | 84 [35-152] | 86 [36-135] | 83 [35-152] | .57 |
| Magnesium, mg/dL | 2 [1-3.3] | 2 [1-2.7] | 1.9 [1.5-3.3] | .40 |
| Baseline characteristics . | Total (N = 100) . | Grade 0-2 ICANS (n = 59) . | Grade ≥3 ICANS (n = 41) . | P . |
|---|---|---|---|---|
| Age, median [range], y | 60 [18-85] | 60 [18-85] | 60 [24-85] | .94 |
| Male | 74 (74) | 46 (78) | 28 (68) | .36 |
| ECOG performance status >0 | 69 (69) | 36 (61) | 33 (80) | .05 |
| Diffuse LBCL* | 77 (77) | 47 (80) | 30 (73) | .70 |
| Ann Arbor stage III-IV | 84 (84) | 50 (85) | 34 (83) | 1 |
| IPI score 3-4 | 55 (55) | 28 (47) | 27 (66) | .10 |
| Prior neuro-psychiatric disease | 41 (41) | 26 (44) | 15 (37) | .54 |
| Disease site | ||||
| Head and neck involvement | 40 (40) | 22 (37) | 18 (44) | .54 |
| Bone marrow biopsy involvement | 22 (22) | 17 (29) | 5 (12) | .05 |
| Prior CNS lymphoma | 8 (8) | 3 (5) | 5 (12) | .27 |
| Previous treatment | ||||
| Previous therapies, median [range], n | 4 [2-15] | 4 [2-15] | 4 [2-11] | |
| Refractory disease | 89 (89) | 53 (90) | 36 (88) | .76 |
| Previous autologous SCT | 29 (29) | 16 (27) | 13 (32) | .66 |
| Previous CAR T therapy | 5 (5) | 4 (7) | 1 (2) | .65 |
| Blood counts, median [range] | ||||
| Absolute neutrophil count, ×109/L | 2.8 [0-20] | 2.8 [0-20] | 2.9 [0-18] | .86 |
| Absolute lymphocyte count, ×109/L | 0.6 [0-2] | 0.6 [0-2] | 0.5 [0-1.4] | .54 |
| Absolute monocyte count, ×109/L | 0.5 [0.02-2] | 0.6 [0.06-2] | 0.4 [0.02-1.4] | .22 |
| Hemoglobin, g/dL | 10 [5-16] | 10 [5-16] | 10 [6-14] | .59 |
| Platelet count, ×109/L | 141 [9-391] | 140 [9-391] | 141 [9-389] | .88 |
| Inflammatory markers, median [range] | ||||
| C-reactive protein, mg/L | 33 [0.3-284] | 23 [0.7-275] | 37 [0.3-284] | .44 |
| Ferritin, mg/L | 812 [13-38 964] | 690 [13-4395] | 1 088 [187-38 964] | .23 |
| Albumin, g/dL | 3.8 [2.4-4.9] | 3.9 [2.5-4.9] | 3.7 [2.4-4.6] | .04 |
| Disease burden markers, median [range] | ||||
| LDH fold increase above ULN | 1.4 [0-17.4] | 1.3 [0-8.4] | 1.6 [0.3-17.4] | .09 |
| LDH > ULN | 74 (74) | 41 (69) | 33 (80) | .25 |
| Renal function and electrolytes, median [range] | ||||
| Creatinine clearance, mL/min | 84 [35-152] | 86 [36-135] | 83 [35-152] | .57 |
| Magnesium, mg/dL | 2 [1-3.3] | 2 [1-2.7] | 1.9 [1.5-3.3] | .40 |
Values are n (%) except as noted. Range of normal for LDH was 313 to 618 U/L for the first 16 patients and 135 to 215 U/L for the subsequent 84. P value reflects comparison of grade 0-2 ICANS to grade ≥3 ICANS. Bold numbers indicate significant P values.
SCT, stem cell transplant; ULN, upper limit of normal.
Includes high-grade B-cell lymphoma compared with transformed follicular lymphoma and primary mediastinal B-cell lymphoma.